Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients.
Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights.
As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.
In reasons released February 7, 2017, the Federal Court
dismissed AstraZeneca's application for a prohibition order
regarding Mylan's naproxen-esomeprazole
product until after the expiration of Patent No. 2,449,098: AstraZeneca Canada Inc v Mylan
Pharmaceuticals ULC, 2017 FC 142. The Court found that Mylan's
allegation of invalidity on the basis of obviousness was
justified.
The preceding is intended as a timely update on Canadian
intellectual property and technology law. The content is
informational only and does not constitute legal or professional
advice. To obtain such advice, please communicate with our offices
directly.
